Effects of Fadrozole in Advanced Breast Cancer
Author Information
Author(s): HR Bonnefoi, IE Smith, M Dowsett, PF Trunet, SJ Houston, RJ da Luz, RD Rubens, RC Coombe, TJ Powles
Primary Institution: Royal Marsden Hospital and Institute of Cancer Research
Hypothesis
Does fadrozole hydrochloride effectively treat advanced breast cancer in post-menopausal women after tamoxifen failure?
Conclusion
Fadrozole is a clinically active aromatase inhibitor with a low incidence of side effects.
Supporting Evidence
- The objective response rate was 17% with no complete responders.
- Fifteen patients (21%) had stable disease and 45 patients (63%) had progressive disease.
- The median duration of objective response was 36 weeks.
- The median time to treatment failure was 12.7 weeks.
Takeaway
Fadrozole is a medicine that helps some women with advanced breast cancer feel better, and it doesn't cause many side effects.
Methodology
This was a double-blind, between-patient comparison of three doses of fadrozole hydrochloride in post-menopausal women with recurrent breast cancer.
Potential Biases
Potential selection bias due to the nature of patient recruitment and previous treatments.
Limitations
The study had a small sample size and some patients were not eligible for evaluation.
Participant Demographics
Post-menopausal women under 80 years with recurrent breast cancer after tamoxifen failure.
Statistical Information
Confidence Interval
95% CI 8.9-27.3%
Want to read the original?
Access the complete publication on the publisher's website